Keros Therapeutics (KROS) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed Keros Therapeutics (KROS) over the past year, losing 4.1% versus a loss of 28.4%. Keros Therapeutics is the larger company by market cap ($219.7 million vs $210.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | TRDA |
|---|---|---|
| Share price | $11.08 | $5.41 |
| Market cap | $219.69M | $210.45M |
| 1-day change | -1.16% | -3.65% |
| YTD return | -44.94% | -45.43% |
| 1-year return | -28.37% | -4.10% |
| 5-year return | -71.25% | — |
| EPS (TTM) | $-3.22 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $16.45 |
| 52-week low | $9.69 | $5.15 |
| Distance from 52-week high | -50.86% | -67.14% |
| Analyst consensus | buy | none |
| Avg. price target upside | +78.97% | +251.53% |
| Average volume | 196.01K | 359.01K |
| Shares outstanding | 19.83M | 38.94M |
| Employees | 92 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed KROS by 24.3 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
KROS vs TRDA FAQ
Which is bigger, Keros Therapeutics or Entrada Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $219.69M compared with $210.45M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, KROS or TRDA?
TRDA returned -4.10% over the past 12 months, compared with -28.37% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.